Skip to main content
SpringerPlus
Figure 2 | SpringerPlus

Figure 2

From: Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL

Figure 2

Relative dose intensities of idarubicine (A) and etoposide (B) during cycles 1 to 5. Relative dose intensities: actually applied doses/planned doses in relation to time/intended times are given in boxplots (upper limit of box: upper quartile, line within box: median, lower limit of box: lower quartile, whisker: last value within one and a half box lengths, more distant values are outliers).

Back to article page